Calculi

Grant will lead to the creation of USDHub, a novel research tool bringing together research and clinical data from hundreds of thousands of kidney stone patients of all ages PHILADELPHIA, Oct. 15, 2024 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) and Vanderbilt University Medical Center were awarded a $7.37 million RC2 grant from the National Institutes of Health (NIH) to lead a five-year multisite project across the U.S. focused on kidney stone disease research. Continue Reading Dr. Gregory Tasian Led by CHOP pediatric urologist, Gregory Tasian, MD, MSc, MSCE and Vanderbilt University Medical Center urologist, Ryan Hsi, MD, the goal of this initiative is to establish a new research tool called the Urinary Stone Disease Hub (USDHub), which will aggregate data from across healthcare systems and research networks into one comprehensive platform drawing data from a cohort of more than 230,000 patients suffering from kidney stone disease. Urinary stone disease is a painful condition that can cause a substantial amount of suffering for affected patients. The prevalence of kidney stones is about 11% in Americans, and kidney stones send more than half a million patients to the emergency room each year, according to the National Kidney Foundation. Although urinary and kidney stones are traditionally thought of as an adult diagnosis, kidney stones in children are becoming more common, and CHOP clinicians encounter them daily. To address the unique needs of children with kidney stones, CHOP created the Pediatric Kidney Stone Center, a multidisciplinary program within its Divisions of Urology and Nephrology that is solely dedicated to the dietary, medical, and surgical management of kidney stones. There have been few advancements in the diagnosis and management of urinary stone disease, partly due to a lack of datasets that contain clinically important information about individuals with urinary stone disease across the lifespan. To help address these challenges, USDHub will draw from medical expertise across adult and pediatric urology and nephrology and combine informatics and AI to establish a novel data resource that includes clinically important information from CT images, clinical notes, stone composition, and 24-hour urine labs, which are not available in existing research databases. "We see this painful condition more frequently now, but strong evidence to support decisions about treating children is lacking because urinary stone disease was once rare," said Tasian, who holds the Cheers for CHOP Chair in Clinical Epidemiology of Pediatric Urological Disease. "Opportunities exist both for expanding the evidence base around the management of kidney and urinary stones and for improving the research process itself." In addition to the work being led by Drs. Tasian at CHOP and Hsi at Vanderbilt, USDHub will involve seven other sites involved are part of the STAR and PEDSnet, which are two PCORnet clinical research networks that have standardized electronic health record data. In addition to CHOP and Vanderbilt University Medical Center, USDHub sites include University of North Carolina, Medical University of South Carolina, Duke University, Texas Children's Hospital, Nationwide Children's Hospital, Lurie Children's Hospital of Chicago and Cincinnati Children's Hospital. "USDHub will be a collaborative effort to synergize efforts and expertise across adult and pediatric stone disease, and to engage patients and caregivers in the design process to ensure that our sustainable data access model meets their needs," Tasian said. "This program will finally provide us with longitudinal data and eliminate our reliance on single-center data sources that segregate pediatric and adult patients. We see the potential to significantly accelerate and improve urinary stone disease research." This research is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grant 1RC2DK140865-01). About Children's Hospital of Philadelphia: A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit . Contact: Kaila Revello Children's Hospital of Philadelphia (610) 457-5916 [email protected] SOURCE Children's Hospital of Philadelphia WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

WEDNESDAY, Aug. 28, 2024 -- For adults with kidney stones, increasing thiazide dose is associated with greater reductions in calcium, which are negatively associated with symptomatic stone events, according to a research letter published online Aug. 22 in JAMA Network Open . Ryan S. Hsi, M.D., from the Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues quantified the association between thiazide dose and calcium reduction and correlating calcium changes with symptomatic stone events in a cohort study. Data were included for 634 adults with kidney stones who underwent initial 24-hour urine collection for stone risk assessment. Changes in calcium were assessed based on low, medium, and high thiazide doses. Participants were assigned to terciles based on the magnitude of the calcium change. The researchers observed significant associations between higher thiazide doses and greater 24-hour mean and percentage calcium reductions (low dose: −79.3 mg/d [−18.9 percent]; medium dose: −94.1 mg/day [−25.5 percent]; high dose: −104.5 mg/day [−28.4 percent]). At four years, the adjusted cumulative incidence of a symptomatic stone event was 28.8, 19.5, and 18.0 percent, respectively, for patients in the low, medium, and high terciles of calcium change after thiazide prescription. "For individuals prescribed thiazides for stone prevention, it may be beneficial to monitor calcium excretion and adjust dose and diet to attain an adequate reduction in urine calcium," the authors write. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Full Launch of CVAC System Announced, Following Successful Early User Evaluation with Physicians Reporting 99% Median Stone Clearance PLEASANTON, Calif.--(BUSINESS WIRE)-- Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups. During his presentation, Dr. Chi also shared late-breaking analysis of one-year data that showed a dramatically lower number of emergency department visits, hospitalization and/or retreatment events for SURE patients compared to URS patients. “Based on our study results, the SURE procedure was determined to be a safe kidney stone treatment that delivers consistently higher stone clearance and lower residual stone volume when compared with URS,” reported Dr. Chi. “This efficacy and safety data, coupled with patient outcomes through the first year of follow up indicates significant promise for SURE procedure using the CVAC System as a potential new gold standard of treatment.” Calyxo recently introduced a redesigned CVAC System, which is an all-in-one, complete stone clearance device integrating ureteroscopy, laser lithotripsy, irrigation and aspiration. In the early user evaluation, 47 urologists performed 152 cases with the CVAC System and reported an impressive 99% median stone clearance, assessed visually at the end of the procedure. Further, the performance of the CVAC System was judged to be “better than a ureteroscope” in 98% of cases. Finally, in the 70 patients who were expected to require more than one ureteroscopic procedure, physicians believed that CVAC helped avoid the second procedure 77% of the time. These results were collected through physician surveys following the procedure and clinical studies are planned to confirm these findings. “The AUA meeting was a landmark event for Calyxo and for patients suffering from kidney stones,” said Joe Catanese, PhD, Calyxo’s President & CEO. “Urologist feedback on the new CVAC System and the associated clinical evidence was overwhelmingly positive. We look forward to making the technology more widely available to help more patients in the coming months.” Approximately 10% of people in the U.S. will have a kidney stone at some point in their lives, according to the AUA. Kidney stone disease is a painful condition that brings with it significant healthcare costs (Current Urology Reports estimates $4.1 billion in annual direct treatment costs by 2030). “CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc. About Calyxo, Inc. Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com.